



RTP TV

NON-HODGKIN'S
LYMPHOMA/CHRONIC
LYMPHOCYtic LEUKEMIA

Select Publications

Ardeshta KM et al. **An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis.** *Proc ASH 2010*;Abstract 6.

Coiffier B et al. **Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naïve or rituximab-sensitive, follicular lymphoma: A randomised phase 3 trial.** *Lancet Oncol 2011*;[Epub ahead of print]. Abstract

Fowler N et al. **The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: Results from a Phase I study.** *Proc ASH 2010*;Abstract 964.

Gisselbrecht C et al. **Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis.** *Proc ASCO 2011*;Abstract 8004.

Hagenbeek A et al. **⁹⁰Y-ibritumomab tiuxetan (Zevalin®) consolidation of first remission in advanced-stage follicular non-Hodgkin's lymphoma: Updated results after a median follow-up of 66.2 months from the international, randomized, phase III First-Line Indolent Trial (FIT) in 414 patients.** *Proc ASH 2010*;Abstract 594.

Hallek M et al. **Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial.** *Lancet 2010*;376(9747):1164-74. Abstract

Horning SJ et al. **Interim positron emission tomography scans in diffuse large B-cell lymphoma: An independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.** *Blood 2010*;115(4):775-7. Abstract

Salles G et al. **Rituximab maintenance for 2 years with high tumor burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomized controlled trial.** *Lancet 2011*;377(9759):42-51. Abstract

A phase II study of VcR-CVAD with rituximab maintenance for untreated mantle cell lymphoma. NC00433537.

A randomized phase II trial of maintenance vs consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma. NCT00310037.

Bendamustine hydrochloride and rituximab with or without bortezomib followed by rituximab with or without lenalidomide in treating patients with high-risk stage II, stage III, or stage IV follicular lymphoma. NCT01216683.

Phase III trial of combined immunochemotherapy with FCR versus BR in previously untreated CLL. NCT00769522.

Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [F]FG-PET scanning. NCT00274924.

Rituximab in treating patients with low tumor burden indolent non-Hodgkin's lymphoma. NCT00075946.